Abstract
Regenerative cell therapies are emerging as the next major development in medicine. Stem cell therapies are defined as any treatment based on viable human stem cells including adult stem cells, embryonic stem cells, and induced pluripotent stem cells. Their ability to self-renew and potential to differentiate into multiple cell types has led to many clinical trials for tissue regeneration, immune modulation, and cancer therapy among other indications. The challenges surrounding commercial viability and clinical uptake of novel therapies are related to difficulties in establishing clinical utility and cost-effectiveness. Only recently has gender bias come to light as a potentially critical pitfall in translational research. Future stem cell strategies should be based on research that has considered sex as a biological variable throughout the biomedical development spectrum to maximize positive outcomes and avoid gender bias. In this review, we focus on the implications of biological sex on translational regenerative stem cell therapies, and consider the limitations of the present body of knowledge.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
